| Identification | Back Directory | [Name]
A 582941 | [CAS]
848591-90-2 | [Synonyms]
A 582941
A 582941; A582941
A-582941 dihydrochloride
Octahydro-2-methyl-5-(6-phenyl-3-pyridazinyl)-pyrrolo[3,4-c]pyrrole
Pyrrolo[3,4-c]pyrrole, octahydro-2-Methyl-5-(6-phenyl-3-pyridazinyl)-, dihydrochloride
Pyrrolo[3,4-c]pyrrole, octahydro-2-methyl-5-(6-phenyl-3-pyridazinyl)-, hydrochloride (1:2)
(3aR,6aS)-2-methyl-5-(6-phenylpyridazin-3-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole
2-methyl-5-(6-phenylpyridazin-3-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole:dihydrochloride | [Molecular Formula]
C17H21ClN4 | [MOL File]
848591-90-2.mol | [Molecular Weight]
316.83 |
| Hazard Information | Back Directory | [Uses]
A 582941 has been shown to provide glycogen synthase kinase-3β activation and α7 nicotinic receptors in Aβ1-42-induced tau phosphorylation in PC12 cells, which is useful in neurodegeneration associated with Alzheimer''s disease research. | [Biological Activity]
a 582941 is a highly selective partial agonist of α7 nicotinic acetylcholine receptors (nachrs), with an ec50 value of 4260 nm to human α7 nachrs [1].nachrs are a family of pentameric ligand-gated ion channels. they are derived from multiple α (α2-α10) and β (β2-β4) subunit genes. α7 nachr receptor exhibits higher ca2+ permeability than other nachr combinations. these receptors modulate the release of multiple neurotransmitters, including acetylcholine (ach), glutamate, and gaba [1].in flipr, a 582941 did not activate recombinant heteromeric nachrs (α4β2, α3β2, α3β4, or α4β4) according to ca2+ dynamics results. in imr-32 cells expressing native human α3β4 nachrs, a 582941 did not produce an agonist effect (with an efficacy less than 20% at concentrations up to 100,000 nm). in xenopus oocytes expressing an α9α10 nachr construct, a 582941 at concentrations up to 100,000 nm did not evoke currents. with respect to nachrs, a 582941 activated only the homomeric α7 subtype [1].in a rat model of short-term memory based on olfactory cues, saline-treated adults used investigation times during the second session nearly equal to the first session, exhibiting little recognition of the juvenile. treatment with a 582941 in adult rats resulted in a dose-related reduction in the exploration time during the second session compared with the first session, exhibiting improved recognition of the juvenile [1]. | [storage]
Desiccate at RT | [References]
[1]. tietje kr, anderson dj, bitner rs, et al. preclinical characterization of a-582941: a novel α7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. cns neuroscience & therapeutics, 2008, 14(1): 65-82. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|